News

Biovian and Remedium collaborate on AAV gene therapy

23 March 2023 | 10:00 am The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L […]
News

Avoid broken cold chains – A 5 step introduction

22 March 2023 | 1:41 pm John Coleman, Business Unit Director at YSDS Life Science, guides you through the steps to securing the deliveries of your temperature sensitive goods. Logistics is a complex, and very important, issue for the life science industry. Products have to arrive on time and in the right place for the patients in a cost effective manner, […]
News

Oligos – The medicines of the future?

22 March 2023 | 12:05 pm What if we could silence certain genes to treat a wide range of medical conditions, from genetic conditions to infectious diseases, and even cancer? It may sound like science fiction, but for some rare diseases it’s already a reality through the use of oligonucleotide therapeutics, sometimes referred to as the medicines of the future. But […]
News

Aqilion to recieve 20.1 million SEK

22 March 2023 | 8:36 am In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry out an issue with priority for existing owners. The issue was carried out during the third quarter of 2022 as an issue of units, which […]
News

The state of Danish research examined in a new report

22 March 2023 | 8:22 am In the report “The scientific impact of Danish research 1980-2020,” the researchers behind the study state that the scientific impact of Danish research has been on the decline for a number of years. The report was commissioned and funded by the Novo Nordisk Foundation and VILLUM FONDEN and is an update of the report “Fostering […]
News

Spot-checking measurements of environmental conditions

21 March 2023 | 4:24 pm Spot-checking is a less time-consuming process than calibration, in part because the calibration process can include as-found data, adjustment (if necessary), and as-left data whereas spot-checking is a verification that the unit under test is still within specification. Field spot-checking is a common way to determine the measurement accuracy of a fixed measurement instrument between […]
News

FluoGuide awarded prestigious grant

21 March 2023 | 8:28 am Innovation Fund Denmark (Innovationsfonden) has awarded its largest grant for research and development of photothermal therapy to a consortium of four academic groups and FluoGuide. The grant valued at DKK 49.1 million (approx. EUR 6.6 million or SEK 75.6 million) structured through a combination of a cash contribution from Innovation Fund Denmark (50%) and a […]
News

XNK receives certificate of GMP compliance of a manufacturer

20 March 2023 | 8:29 am The company has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies. “We are very happy to receive this license. It is an important milestone for XNK, and we are now well positioned […]
News

Orion’s darolutamide approved for additional prostate cancer indication in China

20 March 2023 | 8:23 am The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing […]
News

Affibody presents topline 12-week data

20 March 2023 | 8:20 am Affibody has announced that data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be presented. The data from the open label Part A, presented at the American Academy of Dermatology (AAD) Annual Meeting in New Orleans, USA, demonstrated that […]